Sanofi, Glaxo sign up for vaccine R&D projects under new Gates initiative

John Carroll In its joint venture, Glaxo will front $ 1.8 million for work on the thermostability of vaccines. GSK will set out to make adjuvants–used to boost the effectiveness ...

GSK closing plant ASAP, gives workers pay instead of notice

Eric Palmer GlaxoSmithKline has again said it will close a consumer healthcare plant in New Jersey and move production to a facility in New York. But instead of giving the usual 60-day ...

Neovasc Inc. Announces Publication of Positive Tiara Preclinical Data in the Journal JACC: Cardiovascular Interventions

barbara.lempert -Preclinical Studies Show Innovative Transcatheter Product to Treat Mitral Regurgitation is Safe, Technically Feasible and Results in a Well-Functioning Mitral Bioprosthesis- ...

Eisai slashes U.K. R&D jobs in ‘global’ restructuring

John Carroll Japan's Eisai is slashing 20 R&D jobs and eliminating some 30 consultants contracts in the UK as part of a global R&D restructuring, according to a local spokesperson ...

Suffering Dendreon puts itself on the block, Bloomberg says

Tracy Staton Dendreon is getting tired of soldiering on alone. As Bloomberg reports, the Seattle-based company is casting about for buyers as its prostate cancer treatment ...

Merck sales slump again, but cost cuts keep earnings coming

Tracy Staton On the Big Pharma scorecard, Merck remains on a downward slide. Yes, third-quarter earnings beat estimates, but expectations were low, and it was cost-cutting that delivered ...

Ethicon Receives 510(k) Clearance

barbara.lempert Ethicon Receives 510(k) Clearance for New HARMONIC ACE®+ 7 Shears with Advanced Hemostasis Breakthrough technology in ultrasonic energy designed to improve surgeon ...

Booming Regeneron gets the dirt flying on big R&D expansion

John Carroll With blockbuster sales of Eylea spurring some gangbuster projections for Regeneron's future, the booming biotech today launched construction of a 300,000-square-foot ...

Booming Regeneron adds to R&D footprint in NY

Carly Helfand With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron needs some more space. FiercePharma News

Tweets of the day, 10/28/2013

chris.truelove by Christiane Truelove I am on deadline again, so it will be a short roundup today. But here is what I found of interest.   @charlesornstein: New @ProPublica: Should ...

UPDATED: The ax drops at troubled Merck as big restructuring gets underway

John Carroll The pink slips are starting to fly at Merck R&D. The rumor mill was running full tilt on Monday morning, with comments flowing across Twitter that planned layoffs are ...

Top 10 Drug Patent Losses of 2014

Tracy Staton FiercePharma News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS